Ankylosing Spondylitis Market Expected to Reach USD 9.5 Billion by 2032 at 6.5% CAGR

PHILADELPHIA, N.Y. - Nov. 26, 2025 - PRLog -- According to the latest report by Acumen Research and Consulting, the global Ankylosing Spondylitis Market is on a strong upward trajectory. The market was valued at USD 5.1 Billion in 2022 and is expected to grow to USD 9.5 Billion by 2032, registering a compound annual growth rate (CAGR) of 6.5% from 2023 to 2032.

This anticipated Ankylosing Spondylitis Market Growth is driven by increasing diagnosis rates, expanding treatment options, and growing awareness of this chronic inflammatory condition.

Market Overview

Ankylosing Spondylitis (AS) is a chronic inflammatory autoimmune disease that primarily affects the spine and sacroiliac joints, often causing pain, stiffness and, over time, reduced mobility. Improved diagnostic methods and greater patient awareness are contributing to earlier detection and growing demand for AS therapies.

The rising global prevalence of AS, along with advances in treatment—including biologics and targeted therapies—is propelling expansion of the global AS market.

Ankylosing Spondylitis Market Statistics

• Market Size (2022): USD 5.1 Billion
• Forecast Market Size (2032): USD 9.5 Billion
• Compound Annual Growth Rate (2023–2032): 6.5 %

Download Sample Report: https://ln.run/13Q04

Ankylosing Spondylitis Market Drivers & Dynamics

Rising Prevalence & Early Diagnosis

Increasing awareness, better diagnostic tools, and a growing pool of diagnosed patients have driven the demand for treatments for Ankylosing Spondylitis. This trend boosts the overall market size and potential for long-term growth.

Growing Demand for Medication-Based Treatments

In 2022, medication dominated the treatment segment, accounting for over 62% of total market share — underlining the strong reliance on drugs (biologics, NSAIDs, etc.) in managing AS globally.

Ankylosing Spondylitis Market Regional Leadership & Emerging Markets

In 2022, the North America region led the market, capturing over 43% share — thanks to a well-established healthcare infrastructure and high AS diagnosis and treatment rates.

Meanwhile, the Asia-Pacific region is projected to grow at a comparatively faster pace through 2032, driven by improving healthcare access and rising awareness.

Ankylosing Spondylitis Market Trends & Challenges

The AS market is witnessing several notable trends: increased uptake of biologic therapies (e.g. TNF inhibitors, IL-17 inhibitors), early diagnosis and disease-management awareness, and rising patient support and treatment access initiatives.

However, challenges persist — including disease complexity, variability of symptoms, high cost of biologics, and access disparities across regions.

Read Full News at Globenewswire: https://www.globenewswire.com/news-release/2023/09/13/2742669/0/en/Ankylosing-Spondylitis-Market-Size-Positioned-for-a-Projected-CAGR-of-6-5-to-Achieve-a-Valuation-of-USD-9-5-Billion-by-2032.html